Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products

BACKGROUND: Hemophilia B requires replacement therapy with factor IX (FIX) coagulation products to treat and prevent bleeding episodes. A recently introduced extended half-life (EHL) recombinant FIX replacement product provided the opportunity to compare the amount of dispensed factor and expenditur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tortella, Bartholomew J., Alvir, José, McDonald, Margaret, Spurden, Dean, Fogarty, Patrick F., Chhabra, Amit, Pleil, Andreas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397749/
https://www.ncbi.nlm.nih.gov/pubmed/29363389
http://dx.doi.org/10.18553/jmcp.2018.17212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397749/
https://www.ncbi.nlm.nih.gov/pubmed/29363389
http://dx.doi.org/10.18553/jmcp.2018.17212

Ejemplares similares